Cross-Sector entity
Of the tracked stories, 2 of 2 also mention AbbVie, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention EPCORE DLBCL-1, all published on August 1, 2026.
2 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention AbbVie, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention EPCORE DLBCL-1, all published on August 1, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering EPCORE DLBCL-1. Shared-story counts are live from our verified record — not editorial picks.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
EHA 2026 Presentation
Additional study results presented at the European Hematology Association Congress.
Topline Results Announced
Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Source: finanznachrichten.de · stockhouse.com
